Galcanezumab
- Generic Name
- Galcanezumab
- Brand Names
- Emgality
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1578199-75-3
- Unique Ingredient Identifier
- 55KHL3P693
- Background
Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin gene-related peptide (CGRP). Although several small-molecule CGRP receptor antagonists have been developed, humanized monoclonal antibodies like galcanezumab are specifically designed to selectively bind to CGRP entities with high potency. Given this t...
- Indication
Galcanezumab is indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.
- Associated Conditions
- Episodic Cluster Headache, Migraine
- Associated Therapies
- -
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 986
- Registration Number
- NCT02614196
- Locations
- ๐บ๐ธ
Neurology & Neuroscience Associates, Inc., Akron, Ohio, United States
๐บ๐ธCatalina Research Institute, LLC, Montclair, California, United States
๐บ๐ธAxiom Research, Apple Valley, California, United States
Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 862
- Registration Number
- NCT02614183
- Locations
- ๐บ๐ธ
Orange Grove Family Practice, Tucson, Arizona, United States
๐บ๐ธTerritory Neurology & Research Institute, Tucson, Arizona, United States
๐บ๐ธArkansas Clinical Research, Little Rock, Arkansas, United States
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 270
- Registration Number
- NCT02614287
- Locations
- ๐บ๐ธ
New England Institute for Clinical Research, Stamford, Connecticut, United States
๐บ๐ธSunrise Clinical Research, Hollywood, Florida, United States
๐บ๐ธCalifornia Medical Clinic for Headache, Santa Monica, California, United States
A Study of Galcanezumab in Healthy Participants
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 178
- Registration Number
- NCT02576951
- Locations
- ๐บ๐ธ
Covance, Dallas, Texas, United States
A Study Of Galcanezumab In Participants With Episodic Cluster Headache
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 109
- Registration Number
- NCT02397473
- Locations
- ๐บ๐ธ
New England Institute for Clinical Research, Stamford, Connecticut, United States
๐บ๐ธDent Neurological Institute, Amherst, New York, United States
๐บ๐ธMayo Clinic-Jacksonville, Jacksonville, Florida, United States
A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2018-11-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 414
- Registration Number
- NCT02163993
- Locations
- ๐บ๐ธ
Clinical Research Advantage, Gilbert, Arizona, United States
๐บ๐ธPharmaSite Research Inc, Baltimore, Maryland, United States
๐บ๐ธMedical Center for Clinical Research, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.